EGFR and lung cancer: Therefore, we aim to predict molecular features of EGFR‐mutated lung cancer, including the emergence of secondary EGFR‐T790M mutation and the clearance of EGFR ctDNA, by dynamically monitoring STMs during targeted therapy.